{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:29:44Z","timestamp":1787239784190,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00824-6","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:06Z","timestamp":1787237586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vutrisiran in Transthyretin Amyloidosis: A Narrative Review"],"prefix":"10.1007","author":[{"given":"Kamela","family":"Lybeshari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-1543","authenticated-orcid":false,"given":"Genevieve","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"1","key":"824_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"824_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139.","journal-title":"Amyloid"},{"key":"824_CR3","unstructured":"Amvuttra [Package insert]. Alnylam\u00ae Pharmaceuticals. Updated March 2025. https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/amvuttra-us-prescribing-information.pdf. Accessed 16 Nov 2025."},{"key":"824_CR4","unstructured":"Fontana M. Cardiac amyloidosis: epidemiology, clinical manifestations, and diagnosis. UpToDate. Updated 2024. https:\/\/ff.uptodate.com\/contents\/cardiac-amyloidosis-epidemiology-clinical-manifestations-and-diagnosis\/print. Accessed 15 Nov 2025."},{"issue":"1","key":"824_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344.","journal-title":"N Engl J Med"},{"key":"824_CR6","unstructured":"How RNAi works. Alnylam\u00ae Pharmaceuticals. RNAi therapeutics. https:\/\/www.alnylam.com\/our-science\/the-science-of-rnai. Accessed 15 Nov 2025."},{"issue":"5","key":"824_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","volume":"87","author":"MM Kittleson","year":"2025","unstructured":"Kittleson MM, Ambardekar AV, Cheng RK, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. JACC. 2025;87(5):549\u201365.","journal-title":"JACC"},{"key":"824_CR8","unstructured":"Vutrisiran. UpToDate. Updated 2025. Accessed 15 Nov 2025."},{"issue":"17","key":"824_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178651","volume":"26","author":"A Shevelev","year":"2025","unstructured":"Shevelev A, Pozdniakova N, Generalov E, Tarasova O. SiRNA therapeutics for the treatment of hereditary diseases and other conditions: a review. Int J Mol Sci. 2025;26(17):8651.","journal-title":"Int J Mol Sci"},{"key":"824_CR10","unstructured":"Patisiran. UpToDate. Updated 2025. Accessed 15 Nov 2025."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00824-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:14Z","timestamp":1787237594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00824-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":10,"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00824-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kamela Lybeshari, Huy Pham, and Genevieve Hale declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KL, HP, and GH performed conceptualization, data curation, analysis, investigation, methodology, validation, visualization, writing, reviewing, and editing. HP and GH were responsible for project administration and providing resources and supervision. All authors have read and approved the final version of the manuscript.","order":2,"name":"Ethics","label":"Authors' contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing not applicable to this article as no datasets were generated for it.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}